Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Genmab ( (GMAB) ) just unveiled an announcement.
Genmab announced its financial results for the first half of 2025, reporting a 19% increase in revenue to $1,640 million compared to the same period in 2024. This growth was primarily driven by higher royalties from DARZALEX and Kesimpta, as well as increased EPKINLY sales. The company also highlighted significant progress in its clinical programs, including a submission to the FDA for Epcoritamab and promising data for Rinatabart sesutecan in endometrial cancer. Genmab’s operating profit rose to $548 million, and the company updated its revenue and operating profit guidance for 2025, reflecting higher royalty revenues.
The most recent analyst rating on (GMAB) stock is a Hold with a $31.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
Spark’s Take on GMAB Stock
According to Spark, TipRanks’ AI Analyst, GMAB is a Outperform.
Genmab’s strong financial performance, characterized by robust profitability and a solid balance sheet, is the primary driver of its stock score. Technical analysis suggests some short-term bearish momentum, but the stock remains stable in the long term. Valuation metrics indicate a reasonable price relative to earnings, supporting a positive outlook.
To see Spark’s full report on GMAB stock, click here.
More about Genmab
Genmab A/S is a biotechnology company based in Denmark, specializing in the development of antibody therapeutics for the treatment of cancer. The company focuses on innovative therapies and has a strong pipeline of products, including Epcoritamab and Rinatabart sesutecan, which are advancing in clinical trials.
Average Trading Volume: 1,361,337
Technical Sentiment Signal: Sell
Current Market Cap: $13.75B
See more insights into GMAB stock on TipRanks’ Stock Analysis page.